REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 1.49 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $50 | -100.0% | 500 | -64.3% | 0.00% | -100.0% |
| Q3 2021 | $140,000 | -23.5% | 1,400 | +7.7% | 0.00% | 0.0% |
| Q2 2021 | $183,000 | -71.1% | 1,300 | -68.0% | 0.00% | -66.7% |
| Q2 2020 | $634,000 | +15.5% | 4,068 | +6.8% | 0.00% | 0.0% |
| Q1 2020 | $549,000 | -29.4% | 3,810 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $778,000 | +47.3% | 3,810 | -42.3% | 0.00% | +200.0% |
| Q3 2019 | $528,000 | +36.8% | 6,600 | +61.0% | 0.00% | -50.0% |
| Q2 2019 | $386,000 | +19.1% | 4,100 | +7.9% | 0.00% | +100.0% |
| Q1 2019 | $324,000 | -52.1% | 3,800 | -82.6% | 0.00% | -66.7% |
| Q3 2017 | $677,000 | -1.7% | 21,800 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $689,000 | +347.4% | 21,800 | +220.6% | 0.00% | +200.0% |
| Q1 2017 | $154,000 | +4.1% | 6,800 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $148,000 | -17.3% | 6,800 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $179,000 | +383.8% | 6,800 | +257.9% | 0.00% | – |
| Q2 2016 | $37,000 | – | 1,900 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CPMG Inc | 3,063,567 | $298,453,000 | 49.63% |
| PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE | 150,000 | $14,613,000 | 19.62% |
| Corriente Advisors, LLC | 300,000 | $29,226,000 | 14.82% |
| Prosight Management, LP | 114,554 | $11,160,000 | 5.31% |
| MADDEN SECURITIES Corp | 43,927 | $4,279,000 | 3.18% |
| LBJ Family Wealth Advisors, Ltd. | 30,368 | $2,958,000 | 2.24% |
| Biondo Investment Advisors, LLC | 99,652 | $9,708,000 | 2.10% |
| Cormorant Asset Management, LP | 450,000 | $43,839,000 | 1.69% |
| Duquesne Family Office | 543,901 | $52,987,000 | 1.54% |
| AWH Capital, L.P. | 9,500 | $925,000 | 1.30% |